Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions

Journal of Drugs in Dermatology

Volumn 9, Issue 6, 2010, Pages 677-683

  Brodmerkel, Carrie ^a   Zhu, Yaowei ^a   Jiao, Qun ^a   Cornacoff, Joel ^a   Treacy, George ^a   Mascelli, Mary Ann ^a   Gottlieb, Alice B ^b  

^a CENTOCOR INC   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 23; KEYHOLE LIMPET HEMOCYANIN; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; USTEKINUMAB; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN FUNCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HAPLORHINI; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; TETANUS; ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MACACA; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTIBODIES, MONOCLONAL; HEMOCYANIN; HUMANS; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; MACACA FASCICULARIS; PNEUMOCOCCAL VACCINES; TETANUS TOXOID;

EID: 77955862769     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-240. (Pubitemid 40189432)
2. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577-2587. (Pubitemid 44833335)
3. Van Boxel-Dezaire AH, Hoff SC, Van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol. 1999;45:695-703. (Pubitemid 29260746)
4. Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest. 2003;112:1186-1191. (Pubitemid 38056295)
5. Rogge L, Barberis-Maino L, Biffi M, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med. 185: 825-831.
6. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-146. (Pubitemid 37328691)
7. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-957. (Pubitemid 47300009)
8. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221-242. (Pubitemid 46697908)
9. De Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998;280:1435-1438. (Pubitemid 28264837)
10. Fieschi C, Casanova JL. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol. 2003;3:1461-1464. (Pubitemid 36790405)
11. Van de Vosse E, Hoeve MA, and Ottenhoff TH. Human genetics of intracellular infectious diseases: Molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis. 2004;4:739-749. (Pubitemid 39574345)
12. Ottenhoff T H, Verreck FA, Lichtenauer-Kaligis EG, et al. Genetics, cytokines and human infectious disease: Lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet. 2002;32:97-105. (Pubitemid 34977203)
13. Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007;247:1-11. (Pubitemid 47464175)
14. Looney RJ, Diamond B, Holers VM, et al. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol. 2007;123:235-243. (Pubitemid 46824125)
15. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007;46:608-611. (Pubitemid 46523304)
16. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31: 1356-1361. (Pubitemid 38879202)
17. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34:952-957. (Pubitemid 46774837)
18. Kreuger JG, Ochs HD, Patel P, et al Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: Results of a randomized, single blind study. J Invest Dermatol. 2008;128:2615-2624.
19. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol. 2003;49:816-825. (Pubitemid 37314868)
20. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580-592. (Pubitemid 46220818)
21. De Boer T, Van Dissel JT, Kuijpers TW, et al. Influenza virus vaccination induces interleukin-12/23 receptor β1 (IL-12/23Rβ1)-independent production of gamma interferon (IFN-g) and humoral immunity in patients with genetic deficiencies in IL-12/23Rβ1 or IFN-g Receptor I. Clin Vaccine Immunol. 2008;15:1171-1175.